CLINICAL IMPORTANCE OF ?2 GLYCOPROTEIN I ANTIBODIES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
(Abstract release date: 05/19/16)
EHA Library. Basturk A. 06/09/16; 134928; PB2028
Prof. Abdulkadir Basturk
Contributions
Contributions
Abstract
Abstract: PB2028
Type: Publication Only
Background
Arterial and venous thrombotic events are observed to be higher in BCR-ABL negative Myeloproliferative Neoplasms (MPN) than the normal population. These complications are most important causes of morbidity and mortality. β2 glycoprotein I antibody (β2-GPI Ab) (anti-apolipoprotein H Antibodies) is an important marker of thrombosis in autoimmune diseases.
Aims
In our study, we aimed to evaluate the association of thrombosis and levels of β2-GPI Ab in BCR-ABL negative MPN patients without no genetic predisposition to thrombosis.
Methods
Seventy one patients with BCR-ABL negative MPN and 62 controls were included. Exclusion criteria were present of cardiovascular risk factors, malignancy, active infection, renal failure, and being smaller than 18 years old. Genetic and laboratory testing (such as Factor V Leiden, prothrombin G20210A, activated protein C resistance and homocysteine) for thrombophilia were done in all patients and controls in order to evaluate accurately association between thrombosis and β2-GPI Ab.
Results
Average level of β2-GP Ab was 187 U/ml in all 133 persons (patient and control groups). Average level of β2-GP Ab was 217 U/mL in 71 patients with BCR-ABL negative MPN and 160 U/mL in 62 controls. This difference was statistically significant (p=0.006). Subgroup analysis in patients are seen in Table 1. There was no difference between patients with or without history of thrombosis according to the β2-GPI Ab levels (p=0.144). Tablo 1: Relationship of β2-GPI Ab Level and History of Thrombosis in Patient Group
Conclusion
Despite the known increased risk of thrombosis and hemorrhage in MPNs, mechanisms are still not fully clear. To our knowledge, our study is the first study evaluating the relationship between β2-GPI Ab and thrombosis in BCR-ABL negative MPNs after genetic risk factors excluded. While β2-GPI Ab level was significantly higher in patients with MPN than in normal subjects; no significant difference was determined between patients with or without thrombosis. Alongside β2-GPI Ab, assessment of antibodies against domain IV-V of β2-GP may be useful.
Session topic: E-poster
Keyword(s): Glycoprotein, Myeloproliferative disorder, Thrombosis
Type: Publication Only
Background
Arterial and venous thrombotic events are observed to be higher in BCR-ABL negative Myeloproliferative Neoplasms (MPN) than the normal population. These complications are most important causes of morbidity and mortality. β2 glycoprotein I antibody (β2-GPI Ab) (anti-apolipoprotein H Antibodies) is an important marker of thrombosis in autoimmune diseases.
Aims
In our study, we aimed to evaluate the association of thrombosis and levels of β2-GPI Ab in BCR-ABL negative MPN patients without no genetic predisposition to thrombosis.
Methods
Seventy one patients with BCR-ABL negative MPN and 62 controls were included. Exclusion criteria were present of cardiovascular risk factors, malignancy, active infection, renal failure, and being smaller than 18 years old. Genetic and laboratory testing (such as Factor V Leiden, prothrombin G20210A, activated protein C resistance and homocysteine) for thrombophilia were done in all patients and controls in order to evaluate accurately association between thrombosis and β2-GPI Ab.
Results
Average level of β2-GP Ab was 187 U/ml in all 133 persons (patient and control groups). Average level of β2-GP Ab was 217 U/mL in 71 patients with BCR-ABL negative MPN and 160 U/mL in 62 controls. This difference was statistically significant (p=0.006). Subgroup analysis in patients are seen in Table 1. There was no difference between patients with or without history of thrombosis according to the β2-GPI Ab levels (p=0.144). Tablo 1: Relationship of β2-GPI Ab Level and History of Thrombosis in Patient Group
| β2 Glycoprotein I Ab (U/mL) ** | ||||
| History of Thrombosis | Number (%) | Median | Min-Max | p * |
| Present | 27 (38 %) | 187 | 15-696 | 0.144 |
| Absent | 44 (62 %) | 242.5 | 34-763 | |
| Total | 71 (%100) | 217.0 | 15-763 | |
Conclusion
Despite the known increased risk of thrombosis and hemorrhage in MPNs, mechanisms are still not fully clear. To our knowledge, our study is the first study evaluating the relationship between β2-GPI Ab and thrombosis in BCR-ABL negative MPNs after genetic risk factors excluded. While β2-GPI Ab level was significantly higher in patients with MPN than in normal subjects; no significant difference was determined between patients with or without thrombosis. Alongside β2-GPI Ab, assessment of antibodies against domain IV-V of β2-GP may be useful.
Session topic: E-poster
Keyword(s): Glycoprotein, Myeloproliferative disorder, Thrombosis
Abstract: PB2028
Type: Publication Only
Background
Arterial and venous thrombotic events are observed to be higher in BCR-ABL negative Myeloproliferative Neoplasms (MPN) than the normal population. These complications are most important causes of morbidity and mortality. β2 glycoprotein I antibody (β2-GPI Ab) (anti-apolipoprotein H Antibodies) is an important marker of thrombosis in autoimmune diseases.
Aims
In our study, we aimed to evaluate the association of thrombosis and levels of β2-GPI Ab in BCR-ABL negative MPN patients without no genetic predisposition to thrombosis.
Methods
Seventy one patients with BCR-ABL negative MPN and 62 controls were included. Exclusion criteria were present of cardiovascular risk factors, malignancy, active infection, renal failure, and being smaller than 18 years old. Genetic and laboratory testing (such as Factor V Leiden, prothrombin G20210A, activated protein C resistance and homocysteine) for thrombophilia were done in all patients and controls in order to evaluate accurately association between thrombosis and β2-GPI Ab.
Results
Average level of β2-GP Ab was 187 U/ml in all 133 persons (patient and control groups). Average level of β2-GP Ab was 217 U/mL in 71 patients with BCR-ABL negative MPN and 160 U/mL in 62 controls. This difference was statistically significant (p=0.006). Subgroup analysis in patients are seen in Table 1. There was no difference between patients with or without history of thrombosis according to the β2-GPI Ab levels (p=0.144). Tablo 1: Relationship of β2-GPI Ab Level and History of Thrombosis in Patient Group
Conclusion
Despite the known increased risk of thrombosis and hemorrhage in MPNs, mechanisms are still not fully clear. To our knowledge, our study is the first study evaluating the relationship between β2-GPI Ab and thrombosis in BCR-ABL negative MPNs after genetic risk factors excluded. While β2-GPI Ab level was significantly higher in patients with MPN than in normal subjects; no significant difference was determined between patients with or without thrombosis. Alongside β2-GPI Ab, assessment of antibodies against domain IV-V of β2-GP may be useful.
Session topic: E-poster
Keyword(s): Glycoprotein, Myeloproliferative disorder, Thrombosis
Type: Publication Only
Background
Arterial and venous thrombotic events are observed to be higher in BCR-ABL negative Myeloproliferative Neoplasms (MPN) than the normal population. These complications are most important causes of morbidity and mortality. β2 glycoprotein I antibody (β2-GPI Ab) (anti-apolipoprotein H Antibodies) is an important marker of thrombosis in autoimmune diseases.
Aims
In our study, we aimed to evaluate the association of thrombosis and levels of β2-GPI Ab in BCR-ABL negative MPN patients without no genetic predisposition to thrombosis.
Methods
Seventy one patients with BCR-ABL negative MPN and 62 controls were included. Exclusion criteria were present of cardiovascular risk factors, malignancy, active infection, renal failure, and being smaller than 18 years old. Genetic and laboratory testing (such as Factor V Leiden, prothrombin G20210A, activated protein C resistance and homocysteine) for thrombophilia were done in all patients and controls in order to evaluate accurately association between thrombosis and β2-GPI Ab.
Results
Average level of β2-GP Ab was 187 U/ml in all 133 persons (patient and control groups). Average level of β2-GP Ab was 217 U/mL in 71 patients with BCR-ABL negative MPN and 160 U/mL in 62 controls. This difference was statistically significant (p=0.006). Subgroup analysis in patients are seen in Table 1. There was no difference between patients with or without history of thrombosis according to the β2-GPI Ab levels (p=0.144). Tablo 1: Relationship of β2-GPI Ab Level and History of Thrombosis in Patient Group
| β2 Glycoprotein I Ab (U/mL) ** | ||||
| History of Thrombosis | Number (%) | Median | Min-Max | p * |
| Present | 27 (38 %) | 187 | 15-696 | 0.144 |
| Absent | 44 (62 %) | 242.5 | 34-763 | |
| Total | 71 (%100) | 217.0 | 15-763 | |
Conclusion
Despite the known increased risk of thrombosis and hemorrhage in MPNs, mechanisms are still not fully clear. To our knowledge, our study is the first study evaluating the relationship between β2-GPI Ab and thrombosis in BCR-ABL negative MPNs after genetic risk factors excluded. While β2-GPI Ab level was significantly higher in patients with MPN than in normal subjects; no significant difference was determined between patients with or without thrombosis. Alongside β2-GPI Ab, assessment of antibodies against domain IV-V of β2-GP may be useful.
Session topic: E-poster
Keyword(s): Glycoprotein, Myeloproliferative disorder, Thrombosis
{{ help_message }}
{{filter}}